BACKGROUND: Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating
protein, was the first biologic agent approved for, and the first drug approved in 55 years for …

Objective. To evaluate the use and efficacy of belimumab in academic practices. Belimumab
is a human monoclonal antibody that inhibits soluble B lymphocyte stimulator and has been …

Objectives Systemic lupus erythematosus (SLE) is a chronic, autoimmune disease that
affects multiple organ systems. Belimumab, a targeted human monoclonal antibody, binds to …

Belimumab (Benlysta®) is a fully humanized monoclonal antibody that inhibits B-lymphocyte
stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was …

Objective We undertook this US multicenter continuation study (GlaxoSmithKline study BEL
112233; ClinicalTrials. gov identifier: NCT 00724867) to assess long‐term safety and …

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS).
It is the first biological drug licensed and approved by the US FDA and the European …

Objectives: To assess the efficacy and safety of intravenous (IV) belimumab plus standard
systemic lupus erythematosus (SLE) therapy standard of care (SoC) in Japanese patients …

Background Systemic lupus erythematosus is a heterogeneous autoimmune disease that is
associated with B-cell hyperactivity, autoantibodies, and increased concentrations of B …

ABSTRACT Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated
autoimmune disease which can potentially involve several organs and systems. The …

Introduction: Belimumab is a fully humanised mAb against B lymphocyte stimulator (B-LyS).
It is the first biological drug to be licensed and approved by the US FDA and the European …